Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Takeda Pharmaceutical Co. (TAK) Return on Tangible Equity data is not available for the most recently reported fiscal year, ending 2026-03-31.
| Income Statement Financials | |
$29.74B |
|
$1.27B |
|
$10.37B |
|
$19.37B |
|
$27.04B |
|
$2.70B |
|
$-980.58M |
|
$1.72B |
|
$1.72B |
|
$1.27B |
|
$1.27B |
|
$1.27B |
|
$1.27B |
|
$2.70B |
|
$7.46B |
|
3.15B |
|
3.15B |
|
$0.41 |
|
$0.41 |
|
| Balance Sheet Financials | |
$20.40B |
|
$14.00B |
|
$81.59B |
|
$101.99B |
|
$16.03B |
|
$28.84B |
|
$34.64B |
|
$50.68B |
|
$51.31B |
|
$-9.59B |
|
$51.31B |
|
3.16B |
|
| Cash Flow Statement Financials | |
$6.87B |
|
$-2.44B |
|
$-3.28B |
|
$2.54B |
|
$3.93B |
|
$1.39B |
|
$480.31M |
|
$-2.06B |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Tangible Equity |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|